ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The combination of Chinese and Western Medicine in the management of rheumatoid arthritis: A real-world cohort study across China

Zhong, Linda LD.*; Wang, Rongsheng; Lam, Wai Ching; Zhu, Qi; Du, Peipei; Cao, Pei Hua; Jiang, Ting; Zhang, Yuan Yuan; Shen, Jie; Su, Xiao; Xue, Luan; Mao, Jianchun; Fang, Yong Fei; Gao, Ming Li; Hu, Chun Rong; Peng, Jiang Yun; Gu, Ying; Wei, Qianghua; Huang, Runyue; Lyu, Aiping; Liu, Hongxia*; He, Dongyi*广东省人民医院; 广州中医药大学; 南阳理工学院
Frontiers in Pharmacology2022-10-6DOI: 10.3389/fphar.2022.933519
2被引6阅读
引用收藏
分享

摘要

Objective: To investigate the efficacy of Integrative medicine (IM), compare with Western medicine (WM), in the treatment of rheumatoid arthritis (RA) in a cohort study. Methods: This is a cohort study with recruitment of RA patients from 10 hospitals in China. The primary outcome was change in disease activity score 28 (DAS28) during 4 follow-up visits. Generalized estimating equation (GEE) models that controlled for variables were used to investigate a time trend and assess group differences in the primary outcome and secondary outcomes after propensity score matching (PSM). Results: A total of 3195 patients with RA received IM (n = 1379, 43.2%) or WM (n = 1816, 56.8%). Following 1:1 propensity score matching, 1,331 eligible patients prescribed IM were compared to 1,331 matched patients prescribed WM. The GEE analysis with PSM showed that the IM was more beneficial to significantly decrease the levels of VAS, PGA and PhGA (VAS: odds ratio (OR), 0.76; 95% CI, 0.63-0.92; p = 0.004; PGA: OR, 0.76; 95% CI, 0.64-0.92; p = 0.007; and PhGA: OR, 0.77; 95% CI, 0.64, 0.93; p = 0.004), and reduce DAS28 (OR, 0.84; 95% CI, 0.73-0.98; p = 0.030) in the per-protocol population. Conclusion: This study suggests that compare to WM, IM has advantages in improving RA-related outcomes. However, the statistical significance might not reveal significant clinical difference. Further studies should be focused on specific treatment strategies and/or disease stages.

学科与关键词

关键词
cohort studyintegrative medicinerheumatoid arthritisautoimmune diseaseclinical study
相关
加载中…
  • Conventional disease-modifying anti-rheumatic drugs combined with Chinese Herbal Medicines for rheumatoid arthritis: A systematic review and meta-analysis
    Han, Rong; Ren, Hong Cheng; Zhou, Sitong; Gu, Sherman; Gu, Yue-Yu; Sze, Daniel Man-yuen*; Chen, Meng-Hua*JOURNAL OF TRADITIONAL AND COMPLEMENTARY MEDICINE, 2022, 12(5): 437-446.被引 8
  • Real-world effects of Yishen Tongbi decoction for rheumatoid arthritis: protocol for a prospective, observational, multicenter cohort study with validation against double-blind, randomized, controlled trial
    Liu, Lijuan; Zhu, Fangfang; Xin, Yijun; Zhang, Lu; Hu, Congqi; Xu, Yanping; Zhang, Jinming; Liu, Lingjie; Chen, Guangxing*Frontiers in Pharmacology, 2024, 15: 1320578.
  • Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations
    Jin, Shangyi; Jiang, Nan; Huo, Yuehong; Duan, Xinwang; Fang, Yongfei; Zhao, Cheng; Li, Hongbin; Yang, Min; Huang, Zhirao; Yang, Pingting; Zhang, Hongfeng; Zhan, Feng; Wang, Youlian; Wang, Yanhong; Wu, Chanyuan; Wang, Qian; Hsieh, Evelyn; Li, Mengtao; Tian, Xinping; Zhao, Yan; Zeng, XiaofengAnnals of the Rheumatic Diseases, 2022, 81(7): 1052-1054.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-10-06
卷期
第 13 卷
页码
933519
DOI
10.3389/fphar.2022.933519
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Leading Talents in Shanghai; Shanghai Municipal Health Commission; East China Region based Chinese and Western Medicine Joint Disease Specialist Alliance [ZY (2021-2023)-0302]; 2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund (Guangdong-Hong Kong-Macau Joint Lab) [ZY (2021-2023)-0302]; Science and Technology Commission of Shanghai Municipality [2020B1212030006]; [STCSM Q12 19401934600]

作者

  • Z

    Zhong, Linda LD. (通讯) (第一作者)

    hong kong baptist univ · nanyang technol univ

  • W

    Wang, Rongsheng

    shanghai acad tradit chinese med · shanghai guanghua hosp

查看全部 22 位作者收起作者
  • L

    Lam, Wai Ching

    hong kong baptist univ

  • Z

    Zhu, Qi

    shanghai acad tradit chinese med · shanghai guanghua hosp

  • D

    Du, Peipei

    hong kong baptist univ

  • C

    Cao, Pei Hua

    hong kong baptist univ

  • J

    Jiang, Ting

    shanghai acad tradit chinese med · shanghai guanghua hosp

  • Z

    Zhang, Yuan Yuan

    shanghai acad tradit chinese med · shanghai guanghua hosp

  • S

    Shen, Jie

    shanghai acad tradit chinese med · shanghai guanghua hosp

  • S

    Su, Xiao

    shanghai municipal hosp tradit chinese med

  • X

    Xue, Luan

    shanghai univ tradit chinese med

  • M

    Mao, Jianchun

    shanghai univ tradit chinese med

  • F

    Fang, Yong Fei

  • G

    Gao, Ming Li

  • H

    Hu, Chun Rong

  • P

    Peng, Jiang Yun

  • G

    Gu, Ying

  • W

    Wei, Qianghua

  • H

    Huang, Runyue

    2 · guangdong prov hosp · guangzhou univ chinese med

  • L

    Lyu, Aiping

    hong kong baptist univ

  • L

    Liu, Hongxia (通讯)

    shanghai univ tradit chinese med

  • H

    He, Dongyi (通讯)

    shanghai acad tradit chinese med · shanghai guanghua hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417